Gapdh 8884

MCF7 and ZR75 cell lines were purchased from the American‐Type Culture Collection (ATCC, Manassas, Virginia) and maintained in RPMI 1640 medium supplemented with 10% FBS (Millipore Sigma, St. Louis, MO, USA). HEK293T cell line was purchased from ATCC and maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% FBS. For Fulvestrant (MedChemExpress, Monmouth Junction, NJ, USA) treatment, both MCF7 and ZR75 cells were hormone stripped in phenol red‐free media with 5% dextran‐coated charcoal‐treated FBS (Gemini Bio Products, West Sacramento, CA, USA). After 2 days of incubation, cells were seeded into six‐well plates and treated with Fulvestrant in the presence of 10 nm 17‐β‐estradiol (E2; Sigma). All model cells utilized were free of mycoplasma contamination, and STR DNA profiling of the cells was used to confirm identity. The TFAP2C (sc‐12762) and GFRA1 (sc‐271546) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). The PELP1 antibody (A300‐180A) was purchased from Bethyl Laboratories (Montgomery, TX, USA). The ERα (04‐820) antibody was purchased from Sigma. The p‐ERK1/2 (9106), ERK1/2 (9102), p‐Akt (9271), Akt (9272), RET (3223), GST (2624), and GAPDH (8884) antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). The Ki67 (ab16667) antibody was purchased from Abcam (Cambridge, MA, USA).